Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6N063
UPID:
OGFD2_HUMAN
Alternative names:
-
Alternative UPACC:
Q6N063; B3KT24; Q4KN13; Q6N023; Q9H8K6
Background:
The 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2 plays a crucial role in cellular processes, including the regulation of hypoxia-inducible factors. This protein, through its enzymatic activity, is involved in the hydroxylation of specific substrates, which is essential for oxygen sensing in cells.
Therapeutic significance:
Understanding the role of 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2 could open doors to potential therapeutic strategies. Its involvement in oxygen sensing and regulation provides a unique opportunity for the development of treatments targeting diseases related to oxygen homeostasis.